Revolution Medicines (RVMD)
(Delayed Data from NSDQ)
$47.94 USD
+1.80 (3.90%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $47.91 -0.03 (-0.06%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Income Statements
Fiscal Year end for Revolution Medicines, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 12 | 35 | 29 | 43 | 50 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 12 | 35 | 29 | 43 | 50 |
Selling & Adminstrative & Depr. & Amort Expenses | 499 | 294 | 217 | 154 | 104 |
Income After Depreciation & Amortization | -487 | -258 | -188 | -111 | -54 |
Non-Operating Income | 48 | 9 | 1 | 2 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -440 | -249 | -187 | -109 | -52 |
Income Taxes | -4 | 0 | 0 | 0 | -4 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -436 | -249 | -187 | -108 | -48 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -436 | -249 | -187 | -108 | -48 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -500 | -252 | -178 | -103 | -51 |
Depreciation & Amortization (Cash Flow) | -13 | 7 | 10 | 8 | 3 |
Income After Depreciation & Amortization | -487 | -258 | -188 | -111 | -54 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 113.15 | 80.63 | 72.81 | 54.00 | NA |
Diluted EPS Before Non-Recurring Items | -3.86 | -3.08 | -2.57 | -2.01 | NA |
Diluted Net EPS (GAAP) | -3.86 | -3.08 | -2.57 | -2.01 | -22.33 |
Fiscal Year end for Revolution Medicines, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.74 | 0.00 | 3.82 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.74 | 0.00 | 3.82 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 140.86 | 180.72 | 123.25 | 112.62 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -140.86 | -179.98 | -123.25 | -108.80 |
Non-Operating Income | NA | 24.86 | 18.98 | 10.95 | 10.50 |
Interest Expense | NA | 0.00 | 0.30 | 0.00 | 0.00 |
Pretax Income | NA | -116.00 | -161.19 | -112.30 | -98.30 |
Income Taxes | NA | 0.00 | 0.34 | -3.87 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -116.00 | -161.54 | -108.43 | -98.30 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -116.00 | -161.54 | -108.43 | -98.30 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 164.73 | 141.18 | 109.23 | 106.88 |
Diluted EPS Before Non-Recurring Items | NA | -0.70 | -1.14 | -0.99 | -0.92 |
Diluted Net EPS (GAAP) | NA | -0.70 | -1.23 | -0.99 | -0.92 |